Literature DB >> 1397048

Dopamine receptor occupancy in vivo: behavioral correlates using NNC-112, NNC-687 and NNC-756, new selective dopamine D1 receptor antagonists.

E B Nielsen1, P H Andersen.   

Abstract

The ability of dopamine D2, mixed D1/D2 and selective D1 receptor antagonists, including NNC-112, NNC-687, NNC-756, to inhibit the in vivo binding of [3H]SCH 23390 or [3H]raclopride to dopamine receptors was studied in mice and rats. Furthermore, the dopamine-antagonistic effects of these drugs were also studied in various behavioral models. Significant levels of in vivo receptor blockade were required for antagonism of typical dopamine agonist-mediated behaviors. However, fewer D1 than D2 receptors had to be blocked to produce similar antagonistic effects. Thus, there may be a greater receptor reserve for D2 receptors than for D1 receptors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1397048     DOI: 10.1016/0014-2999(92)90577-q

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

1.  The role of dopaminergic transmission through D1-like and D2-like receptors in amphetamine-induced rat ultrasonic vocalizations.

Authors:  Jennifer M Wright; May R S Dobosiewicz; Paul B S Clarke
Journal:  Psychopharmacology (Berl)       Date:  2012-09-28       Impact factor: 4.530

2.  Tolerability, safety and pharmacokinetics of single dose and multiple dosing of the selective D1 antagonist NNC 01-0687 in healthy subjects.

Authors:  B K Skrumsager; J V Christensen; S Snel; M Seiberling
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

3.  Long-term treatment with low doses of the D1 antagonist NNC 756 and the D2 antagonist raclopride in monkeys previously exposed to dopamine antagonists.

Authors:  H Lublin; J Gerlach; F Mørkeberg
Journal:  Psychopharmacology (Berl)       Date:  1994-04       Impact factor: 4.530

4.  PET examination of [11C]NNC 687 and [11C]NNC 756 as new radioligands for the D1-dopamine receptor.

Authors:  P Karlsson; L Farde; C Halldin; C G Swahn; G Sedvall; C Foged; K T Hansen; B Skrumsager
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity.

Authors:  H Lublin; J Gerlach; L Peacock
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Evaluation of SCH 39166 as PET ligand for central D1 dopamine receptor binding and occupancy in man.

Authors:  P Karlsson; G Sedvall; C Halldin; C G Swahn; L Farde
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

7.  Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients.

Authors:  P Karlsson; L Smith; L Farde; C Härnryd; G Sedvall; F A Wiesel
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

8.  Lack of effect of the dopamine D1 antagonist, NNC 01-0687, on unstimulated and stimulated release of anterior pituitary hormones in males.

Authors:  E Grodum; M Andersen; J Hangaard; O Koldkjaer; C Hagen
Journal:  J Endocrinol Invest       Date:  1998-05       Impact factor: 4.256

9.  Oral administration of NNC 756--a placebo controlled PET study of D1-dopamine receptor occupancy and pharmacodynamics in man.

Authors:  P Karlsson; L Farde; C Halldin; G Sedvall; L Ynddal; M Sloth-Nielsen
Journal:  Psychopharmacology (Berl)       Date:  1995-05       Impact factor: 4.530

10.  Striatal D1 and D2 receptor availability are selectively associated with eye-blink rates after methylphenidate treatment.

Authors:  Şükrü B Demiral; Peter Manza; Erin Biesecker; Corinde Wiers; Ehsan Shokri-Kojori; Katherine McPherson; Evan Dennis; Allison Johnson; Dardo Tomasi; Gene-Jack Wang; Nora D Volkow
Journal:  Commun Biol       Date:  2022-09-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.